Evidence map›Paper›PMID 37982994›Full record

ReviewCurrent hypertension reports2024

Underlying Mechanisms and Treatment of Hypertension in Glomerular Diseases.

Sahar H Koubar, Alejandro Garcia-Rivera, Muner M B Mohamed, John E Hall, Michael E Hall, Mohamed Hassanein

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hypertension reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Hemodynamic simulation andPhysics of fluids (Woodbury, N.Y. : 1994) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Sahar H KoubarDivision of Nephrology and Hypertension, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Alejandro Garcia-RiveraDepartment of Nephrology. Hospital General Regional 46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico.
Muner M B MohamedDepartment of Nephrology, Ochsner Health System, New Orleans, LA, USA.
John E HallDepartment of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA.
Michael E HallDivision of Cardiovascular Disease, Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Mohamed HassaneinDivision of Nephrology and Hypertension, Department of Medicine, University of Mississippi Medical Center, 2500 N State Street, Jackson, MS, USA. mhassanein@umc.edu.
University of Mississippi Medical Center · USMexican Social Security Institute · MXOchsner Health System · USUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review aims to explore the underlying mechanisms that lead to hypertension in glomerular diseases and the advancements in treatment strategies and to provide clinicians with valuable insights into the pathophysiological mechanisms and evidence-based therapeutic approaches for managing hypertension in patients with glomerular diseases. RECENT

findingsIn recent years, there have been remarkable advancements in our understanding of the immune and non-immune mechanisms that are involved in the pathogenesis of hypertension in glomerular diseases. Furthermore, this review will encompass the latest data on management strategies, including RAAS inhibition, endothelin receptor blockers, SGLT2 inhibitors, and immune-based therapies. Hypertension (HTN) and cardiovascular diseases are leading causes of mortality in glomerular diseases. The latter are intricately related with hypertension and share common pathophysiological mechanisms. Hypertension in glomerular disease represents a complex and multifaceted interplay between kidney dysfunction, immune-mediated, and non-immune-mediated pathology. Understanding the complex mechanisms involved in this relationship has evolved significantly over the years, shedding light on the pathophysiological processes underlying the development and progression of glomerular disease-associated HTN, and is crucial for developing effective therapeutic strategies and improving patients' outcomes.

Indexed as

Cardiovascular DiseasesHypertensionKidney DiseasesAntihypertensive AgentsHumansAntihypertensive AgentsAutoimmuneGlomerular diseasesGlomerulonephritisHypertensionImmunosuppressive medicationsProteinuria

Identifiers

PMID37982994
OpenAlexW4388833309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.